Randomized evidence from clinical trials and naturalistic proof collected from pharmacoepidemiology and pharmacovigilance actions equally add into the initial and continual assessment in the benefits and risks of a drug, ie, the harmony between therapeutic efficacy and basic safety risks. Benefit-risk assessment (BRA) mainly relies with a qualitati